

SIRT2 promotes murine melanoma progression through natural killer cell inhibition

**Manchao Zhang^{1,3}, Scarlett Acklin^{1,3}, John Gillenwater¹, Wuying Du¹, Mousumi Patra¹,
Hao Yu¹, Jianhua Yu², and Fen Xia^{1*}.**


¹Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA; ²Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center and Beckman Research Institute, Duarte, California

³These authors contributed equally.

Correspondence:

*Fen Xia, MD, PhD, Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA; Tel: 501-686-7100; Fax: 501-686-7285; E-mail: FXia@uams.edu

Supplemental Figure



Supplemental Figure 1. Intracellular SIRT2 expression does not impact melanoma tumor progression

(A) Western blot showing decreased SIRT2 expression in *Sirt2*-KO B16-F10 cells following *Sirt2* knockout via CRISPR gene editing. *Sirt2*-OE B16-F10 cells overexpress SIRT2 as demonstrated by western blot following transfection with Flag-WT-*Sirt2*. (B) C57BL/6 WT mice were injected with WT, *Sirt2*-OE, and *Sirt2*-KO B16-F10 melanoma cells and tumor development and growth were monitored for 14 days. No significant difference in tumor progression was observed between the cell groups. Data points are mean values \pm SEM. n = 10. One-way ANOVA with post-hoc Tukey HSD test.